Skip to main content
ImmuneCited

Andrographis Figures

49 figures from peer-reviewed research

All Andrographis Arginine Astaxanthin Astragalus Conjugated Linoleic Acid Cordyceps Curcumin Elderberry Glutathione Iron N-Acetylcysteine Omega-3 Fatty Acids (EPA/DHA) Pelargonium sidoides Quercetin Resveratrol Vitamin D Zinc
All Types Chart Diagram Photograph Flowchart Forest Plot Micrograph Other
Fig. 1 Andrographolide protected mice from radiation-induced lung injury. Mice were exposed to 18 Gy irradiation and then treated with the indicated doses of Andrographolide for 4 weeks after irradiation. a Representative images of mice at 8 weeks post-ir
Figure 2 Photograph

Mice exposed to 18 Gy irradiation and treated with varying doses of andrographolide for 4 weeks showed dose-dependent protection from radiation-induced lung injury. Representative images and quantitative data indicate that andrographolide significantly attenuated lung tissue damage.

Inhibition of AIM2 inflammasome-mediated pyroptosis by Andrographolide contributes to amelioration of radiation-induced …

Figure 3
Figure 3 Micrograph

Histological analysis of lung tissue from irradiated mice reveals the extent of inflammatory cell infiltration and fibrosis. Andrographolide treatment appears to reduce these pathological changes in a dose-dependent manner.

Inhibition of AIM2 inflammasome-mediated pyroptosis by Andrographolide contributes to amelioration of radiation-induced …

Figure 4
Figure 4 Chart

Inflammatory cytokine levels in lung tissue were measured following radiation exposure and andrographolide treatment. The data suggest that andrographolide suppresses pro-inflammatory mediator release in irradiated lung tissue.

Inhibition of AIM2 inflammasome-mediated pyroptosis by Andrographolide contributes to amelioration of radiation-induced …

Figure 5
Figure 5 Chart

AIM2 inflammasome activation and caspase-1-mediated pyroptosis play key roles in radiation-induced lung inflammation. This figure presents protein expression data showing andrographolide's inhibitory effects on the AIM2 inflammasome pathway.

Inhibition of AIM2 inflammasome-mediated pyroptosis by Andrographolide contributes to amelioration of radiation-induced …

Figure 6
Figure 6 Chart

Gasdermin D cleavage is a downstream event in pyroptotic cell death triggered by radiation. Western blot analysis demonstrates that andrographolide reduces Gasdermin D processing in macrophages exposed to radiation.

Inhibition of AIM2 inflammasome-mediated pyroptosis by Andrographolide contributes to amelioration of radiation-induced …

Figure 7
Figure 7 Chart

Immunofluorescence or protein analysis reveals that andrographolide prevents AIM2 from binding cytoplasmic DNA and forming active inflammasome complexes. These findings indicate a specific molecular target for andrographolide's protective mechanism.

Inhibition of AIM2 inflammasome-mediated pyroptosis by Andrographolide contributes to amelioration of radiation-induced …

Fig. 7 A graphic illustration of the mechanism of Andrographolide ameliorating radiation-induced lung injury. Andrographolide inhibits Caspase-1-mediated Gasdermin D-dependent pyroptosis in macrophage by preventing AIM2 from translocating into nucleus to
Figure 8 Diagram

Andrographolide ameliorates radiation-induced lung injury by inhibiting Caspase-1-mediated Gasdermin D-dependent pyroptosis in macrophages. This schematic illustrates how the compound prevents AIM2 from translocating into the nucleus, thereby blocking inflammasome assembly and downstream inflammatory cascades.

Inhibition of AIM2 inflammasome-mediated pyroptosis by Andrographolide contributes to amelioration of radiation-induced …

Figure 1
Figure 1 Chart

Experimental results examining early intervention with Kan Jang® to treat upper, with data points illustrating key findings related to BACKGROUND AND AIM: Andrographis paniculata and Eleutherococcus senticosus preparations and their fixed combination, .

Early intervention with Kan Jang® to treat upper-respiratory tract infections: A randomized, …

Figure 2
Figure 2 Chart

Statistical analysis from research investigating early intervention with Kan Jang® to treat upper, comparing treatment groups and control conditions.

Early intervention with Kan Jang® to treat upper-respiratory tract infections: A randomized, …

Figure 3
Figure 3 Chart

Measured parameters from a study evaluating early intervention with Kan Jang® to treat upper, contributing to the overall assessment of BACKGROUND AND AIM: Andrographis paniculata and Eleutherococcus senticosus preparations and their fixed combination, .

Early intervention with Kan Jang® to treat upper-respiratory tract infections: A randomized, …

Figure 4
Figure 4 Chart

Graphical representation of outcomes in a study of early intervention with Kan Jang® to treat upper, highlighting trends observed across experimental conditions.

Early intervention with Kan Jang® to treat upper-respiratory tract infections: A randomized, …

Figure 5
Figure 5 Chart

Quantitative data from a study on early intervention with Kan Jang® to treat upper, presenting measured outcomes relevant to the investigation of BACKGROUND AND AIM: Andrographis paniculata and Eleutherococcus senticosus preparations and their fixed combination, .

Early intervention with Kan Jang® to treat upper-respiratory tract infections: A randomized, …

Figure 6
Figure 6 Chart

Experimental results examining early intervention with Kan Jang® to treat upper, with data points illustrating key findings related to BACKGROUND AND AIM: Andrographis paniculata and Eleutherococcus senticosus preparations and their fixed combination, .

Early intervention with Kan Jang® to treat upper-respiratory tract infections: A randomized, …

Figure 7
Figure 7 Chart

Statistical analysis from research investigating early intervention with Kan Jang® to treat upper, comparing treatment groups and control conditions.

Early intervention with Kan Jang® to treat upper-respiratory tract infections: A randomized, …

Figure 8
Figure 8 Chart

Measured parameters from a study evaluating early intervention with Kan Jang® to treat upper, contributing to the overall assessment of BACKGROUND AND AIM: Andrographis paniculata and Eleutherococcus senticosus preparations and their fixed combination, .

Early intervention with Kan Jang® to treat upper-respiratory tract infections: A randomized, …

Figure 9
Figure 9 Chart

Graphical representation of outcomes in a study of early intervention with Kan Jang® to treat upper, highlighting trends observed across experimental conditions.

Early intervention with Kan Jang® to treat upper-respiratory tract infections: A randomized, …

Figure 10
Figure 10 Chart

Quantitative data from a study on early intervention with Kan Jang® to treat upper, presenting measured outcomes relevant to the investigation of BACKGROUND AND AIM: Andrographis paniculata and Eleutherococcus senticosus preparations and their fixed combination, .

Early intervention with Kan Jang® to treat upper-respiratory tract infections: A randomized, …

Figure 11
Figure 11 Chart

Experimental results examining early intervention with Kan Jang® to treat upper, with data points illustrating key findings related to BACKGROUND AND AIM: Andrographis paniculata and Eleutherococcus senticosus preparations and their fixed combination, .

Early intervention with Kan Jang® to treat upper-respiratory tract infections: A randomized, …

Figure 12
Figure 12 Chart

Statistical analysis from research investigating early intervention with Kan Jang® to treat upper, comparing treatment groups and control conditions.

Early intervention with Kan Jang® to treat upper-respiratory tract infections: A randomized, …

Figure 13
Figure 13 Chart

Measured parameters from a study evaluating early intervention with Kan Jang® to treat upper, contributing to the overall assessment of BACKGROUND AND AIM: Andrographis paniculata and Eleutherococcus senticosus preparations and their fixed combination, .

Early intervention with Kan Jang® to treat upper-respiratory tract infections: A randomized, …

Figure 14
Figure 14 Chart

Graphical representation of outcomes in a study of early intervention with Kan Jang® to treat upper, highlighting trends observed across experimental conditions.

Early intervention with Kan Jang® to treat upper-respiratory tract infections: A randomized, …

Figure 15
Figure 15 Chart

Quantitative data from a study on early intervention with Kan Jang® to treat upper, presenting measured outcomes relevant to the investigation of BACKGROUND AND AIM: Andrographis paniculata and Eleutherococcus senticosus preparations and their fixed combination, .

Early intervention with Kan Jang® to treat upper-respiratory tract infections: A randomized, …

Figure 16
Figure 16 Chart

Experimental results examining early intervention with Kan Jang® to treat upper, with data points illustrating key findings related to BACKGROUND AND AIM: Andrographis paniculata and Eleutherococcus senticosus preparations and their fixed combination, .

Early intervention with Kan Jang® to treat upper-respiratory tract infections: A randomized, …

Figure 17
Figure 17 Chart

Statistical analysis from research investigating early intervention with Kan Jang® to treat upper, comparing treatment groups and control conditions.

Early intervention with Kan Jang® to treat upper-respiratory tract infections: A randomized, …

Page 1 of 3